OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma

September 3rd 2020

Christian U. Blank, MD, PhD, discusses the OpACIN and OPACIN-neo trials examining ipilimumab plus nivolumab in stage III macroscopic melanoma.

Dr. Shah on Early Benefit of Orvacabtagene Autoleucel in Relapsed/Refractory Myeloma

September 3rd 2020

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Leslie on Emerging Therapies in MCL

September 3rd 2020

Lori A. Leslie, MD, lymphoma attending, discusses emerging therapies in mantle cell lymphoma.

Dr. Rizvi on the Utility of Trastuzumab Deruxtecan in NSCLC

September 3rd 2020

Naiyer A. Rizvi, MD, discusses the utility of fam-trastuzumab deruxtecan-nxki in non–small cell lung cancer.

Dr. Pennell on Remaining Challenges in NSCLC

September 3rd 2020

Nathan A. Pennell, MD, PhD, discusses remaining challenges in non–small cell lung cancer.

Dr. Halfdanarson on Investigational Agents in Driver-Negative CRC

September 3rd 2020

Thorvardur (Thor) Halfdanarson, MD, discusses investigational agents that are being evaluated in patients with colorectal cancer who do not harbor genomic alterations.

Dr. Ahmed on the Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

September 3rd 2020

Kamran A. Ahmed, MD, discusses the impact of neratinib on patients with central nervous system metastases and HER2-positive breast cancer.

Dr. Vaishampayan on the Need to Develop Novel Therapies in mRCC

September 3rd 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the need to develop novel therapies for patients with metastatic renal cell carcinoma.

Dr. Jacobson on the ZUMA-5 Trial With Axi-Cel in High-Risk Relapsed/Refractory iNHL

September 2nd 2020

Caron Jacobson, MD, discusses the high-risk patient population within relapsed/refractory indolent non-Hodgkin lymphoma included in the phase 2 ZUMA-5 study.

Dr. Motzer on the TIVO-3 Trial Examining Tivozanib in Advanced RCC

September 2nd 2020

Robert J. Motzer, MD, discusses the results of the phase 3 TIVO-3 trial with tivozanib versus sorafenib in patients with advanced renal cell carcinoma.

Dr. Richter on the Importance of Optimizing Available Therapies in Multiple Myeloma

September 2nd 2020

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma.

Dr. Grothey on Left- Versus Right-Sided Tumors in CRC

September 2nd 2020

Axel Grothey, MD, discusses left- versus right-sided tumors in colorectal cancer.

Dr. Rizvi on Utilizing Molecular Characteristics to Inform Treatment Decisions in NSCLC

September 2nd 2020

Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.

Dr. Moore on Anticipated Impact of the MIRASOL Trial in Platinum-Resistant Ovarian Cancer

September 2nd 2020

Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.

Dr. Nguyen on the Role of Radiation Therapy in High-Risk Prostate Cancer

September 2nd 2020

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.

Dr. Hill on the Challenges of Managing Heavily Pretreated DLBCL

September 2nd 2020

Brian T. Hill, MD, PhD, discusses the challenges of managing heavily pretreated patients with diffuse large B-cell lymphoma.

Dr. Tripathy on the Evolving Treatment Landscape of HER2+ Breast Cancer

September 2nd 2020

Debu Tripathy, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Dr. VanderWalde on Utility of Radiation Therapy in Rectal Cancer

September 1st 2020

Noam VanderWalde, MD, MS, discusses radiation therapy in early-stage versus later-stage rectal cancer.

Dr. Richard on the Evolving Armamentarium in Multiple Myeloma

September 1st 2020

Shambavi Richard, MD, highlights the rapidly evolving armamentarium in multiple myeloma.

Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC

September 1st 2020

Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.